Current CML therapy

• Verfasst von: Hehlmann, Rüdiger [VerfasserIn]
• Titel: Current CML therapy
• Titelzusatz: progress and dilemma
• Verf.angabe: R. Hehlmann
• E-Jahr: 2003
• Jahr: 23 May 2003
• Umfang: 3 S.
• Fussnoten: Gesehen am 13.05.2022
• Titel Quelle: Enthalten in: Leukemia
• Ort Quelle: London : Springer Nature, 1997
• Jahr Quelle: 2003
• Band/Heft Quelle: 17(2003), 6, Seite 1010-1012
• ISSN Quelle: 1476-5551
• DOI: doi:10.1038/sj.leu.2402951
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Cancer Research
• Sach-SW: general
• Sach-SW: Hematology
• Sach-SW: Intensive / Critical Care Medicine
• Sach-SW: Internal Medicine
• Sach-SW: Medicine/Public Health
• Sach-SW: Oncology
• K10plus-PPN: 1801717915

Abstract

Rarely has progress in treatment of leukemia been as dramatic and convincing as with the BCR-ABL tyrosine kinase inhibitor imatinib.1 Imatinib induces remissions of CML as fast as hydroxyurea, achieves rates of cytogenetic remissions that by far exceed those induced by interferon α and has a toxicity profile as favourable as that of hydroxyurea and much superior to that of interferon α.2 In addition, the causal approach of this new drug, which may well serve as a model for new treatment modalities in other neoplasias is reassuring.